To the best of our knowledge, just a small number of JAK2 inhibitors were being tested for cancer therapy on the status phase I or phase II, and only one JAK2 inhibitor, Ruxolitinib (INC424), was approved by Food and Drug Administration (FDA) [14]. This evidence concerns the gene JAK2 and cancer.